Sarepta Therapeutics Eyes 2026 Reset After Rocky Year
Sarepta Therapeutics Inc. ((SRPT)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sarepta Therapeutics’ latest earnings call struck a cautiously optimistic tone, pairing tough headlines around safety events, inventory write-downs and operating losses with strong revenue growth, a solid cash cushion and impressive three‑year data for ELEVIDYS. Management framed 2026 as a reset year, focused on rebuilding confidence in gene therapy, expanding commercial execution and advancing a broad RNA pipeline.
Revenue growth remains resilient despite turbulence
Full-year 2025 revenue reached $2.2 billion, up 16% year over year and underscoring durable demand across the portfolio. Net product revenue of $1.86 billion was split between $966 million from the PMO franchise and $899 million from ELEVIDYS, signaling that the gene therapy is gaining meaningful commercial traction even amid market uncertainty.
Cash generation strengthens balance sheet flexibility
The company ended 2025 with $954 million in cash and investments, increasing its cash position by $89 million in the fourth quarter. Excluding Arrowhead-related flows, Sarepta’s base business generated more than $330 million in positive cash flow in 2025, and management believes the company can be both cash‑flow positive and non‑GAAP profitable in 2026 under reasonable assumptions.
ELEVIDYS data support durable, disease-modifying potential
Three‑year results from the EMBARK Part 1 study showed robust and durable efficacy for ELEVIDYS versus an external control, with a 73% slowing of disease progression in time‑to‑rise and 70% in the 10‑meter walk/run. The NSAA score advantage of 4.39 points at year three, with a highly significant p‑value and no new safety signals, reinforces ELEVIDYS as a potentially disease‑modifying therapy.
PMO franchise delivers stable revenue and high compliance
Sarepta’s PMO products generated $966 million in 2025 net revenue, highlighting the enduring strength of this core business. Fourth‑quarter PMO revenue reached $259 million, driven by EXONDYS at $148 million, VYONDYS at $34 million and AMONDYS at $77 million, with management noting compliance levels consistently above 90% year after year.
siRNA pipeline advances with multiple shots on goal
The company highlighted five clinical-stage siRNA programs, including SRP‑1003 for DM1 and additional efforts in FSHD, IPF, SCA2 and Huntington’s disease via SRP‑1005. Preclinical programs in SCA1 and SCA3 are also progressing, and Sarepta plans preliminary DM1 and FSHD readouts by the end of the quarter with more pharmacodynamic and splicing data anticipated later in 2026.
Regulatory wins and key commercial milestones
ELEVIDYS has now secured traditional approval for ambulatory patients, an important de‑risking step for the franchise. Regulators have also cleared a sirolimus pretreatment study for non‑ambulatory patients, while Sarepta prepares for an FDA meeting aimed at moving AMONDYS and VYONDYS from accelerated to traditional approval on the back of ESSENCE confirmatory data.
Greater visibility into 2026 revenue and collaborations
For 2026, the company guided to net product revenue of $1.2 billion to $1.4 billion, though management advised investors to model toward the lower end given timing risks around ELEVIDYS uptake. Sarepta also expects $450 million to $550 million in collaboration, contract manufacturing and royalty revenue, including a milestone and substantial noncash collaboration income tied to its Roche partnership.
Safety events create near-term demand headwinds
Unanticipated safety events in 2025 triggered temporary regulatory actions and increased caution among physicians and families, pressuring near-term ELEVIDYS demand. Management characterized 2026 as a reset year, with a focus on closing information gaps about risk–benefit, engaging with stakeholders and gradually rebuilding confidence in gene therapy.
Inventory and manufacturing charges weigh on margins
Fourth-quarter cost of sales surged to $399 million, including a $193 million charge made up of a $165 million noncash excess inventory reserve and $28 million of purchase-commitment cancellation fees. For the full year, cost of sales totaled $840 million, with nearly half tied to failed production batches, inventory reserves and other period-specific manufacturing charges.
Headline operating losses mask underlying profitability
Sarepta reported a 2025 GAAP operating loss of $700 million and a non‑GAAP operating loss of $492 million, figures that reflect the heavy charges and restructuring. Management argued that excluding restructuring and Arrowhead transaction costs, the core business would have shown a positive operating profit of $226 million on a GAAP basis and $391 million on a non‑GAAP basis.
Short-term softness and revenue timing risks
Executives cautioned that first-quarter revenue is expected to be roughly flat to down as much as 15% versus the prior quarter, partly because six planned ELEVIDYS infusions were pushed into 2026. Long enrollment-to-infusion timelines mean that new commercial initiatives are unlikely to drive a meaningful revenue acceleration until the second half of 2026 or later.
Non-ambulatory dosing on hold pending new data
Commercial dosing for non‑ambulatory patients was paused after 155 individuals were treated through July 2025, reflecting an abundance-of-caution approach. The ongoing Cohort 8 study, which enrolls about 25 participants with sirolimus prophylaxis, is expected to read out by late 2026, and any broad resumption of non‑ambulatory dosing will depend on those data and subsequent regulatory discussions.
Margin pressures expected to ease as operations normalize
Underlying gross margins were in the low‑80% range in 2025 when excluding the one‑time inventory and batch-related charges, pointing to solid unit economics. For 2026, management expects unit margins to land in the high‑70% range as production volumes reset and fewer period-specific charges are anticipated, suggesting some normalization as the manufacturing system stabilizes.
Guidance points to profitability inflection in 2026
Looking ahead, Sarepta’s 2026 outlook calls for net product revenue of $1.2 billion to $1.4 billion alongside $450 million to $550 million of collaboration and related revenue. With planned non‑GAAP R&D and SG&A spending of $800 million to $900 million and a nearly $1 billion cash balance, the company believes it can turn cash‑flow positive and achieve non‑GAAP profitability next year while continuing to invest in its gene therapy and RNA platforms.
Sarepta’s earnings call painted a picture of a company navigating real near-term turbulence while building a stronger long-term foundation in rare disease. Investors will closely watch ELEVIDYS uptake, the outcome of non‑ambulatory studies and the coming siRNA data, but management’s confidence in its cash runway, margin recovery and 2026 profitability targets suggests the story remains very much in play.
